Sandip P. Patel, MD

Sandip P. Patel, MD, a professor of medicine in the Department of Medicine at the University of California, San Diego (UCSD) and a medical oncologist at the UCSD Moores Cancer Center

Articles

Dr Patel on Toxicities Associated With Immunotherapy-Based Combinations in NSCLC

July 23rd 2025

Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.

Looking Ahead: Future Perspectives and Advancements in EGFRm NSCLC

July 16th 2025

Panelists discuss how future developments in EGFR-mutated non–small cell lung cancer (NSCLC) will focus on biomarker-driven patient selection, rational sequencing strategies, and emerging therapies including cellular therapy and treatments for atypical EGFR mutations.

Balancing Safety and Efficacy With ADC-Based Therapies in Advanced EGFRm Non–Small Cell Lung Cancer

July 16th 2025

Panelists discuss how ADC-based therapies like dato-DXd offer superior efficacy compared with traditional chemotherapy options like docetaxel, while requiring careful monitoring for unique toxicities including ILD, stomatitis, and ocular effects.

TROP2 and Dato-DXd in EGFRm Non–Small Cell Lung Cancer: Evolving Biomarkers and Treatment Strategies

July 9th 2025

Panelists discuss how TROP2-targeted ADC dato-DXd represents another promising option with evolving digital pathology biomarker approaches, though practical implementation and patient selection strategies remain challenging.

Exploring the Potential Role of HER3-DXd in Advanced EGFRm Non–Small Cell Lung Cancer

July 9th 2025

Panelists discuss how HER3-directed ADC patritumab deruxtecan shows promise as a later-line therapy with approximately 30% response rates and intracranial activity, though biomarker selection remains elusive and mechanism of CNS penetration unclear.

Treatment Selection and Sequencing Strategies for Advanced EGFRm NSCLC in the Second-Line Setting

July 2nd 2025

Panelists discuss how second-line treatment selection depends heavily on frontline therapy choice, emphasizing the importance of repeat biopsies to identify resistance mechanisms and considering continuation of TKI with added chemotherapy for patients with controlled CNS disease.

Balancing Safety and Efficacy in the Frontline Management of Advanced EGFRm NSCLC

July 2nd 2025

Panelists discuss how balancing safety and efficacy in frontline regimens involves managing distinct toxicity profiles, with FLAURA2 requiring standard chemotherapy monitoring vs MARIPOSA necessitating complex supportive care for EGFR-related skin toxicity and venous thromboembolism prophylaxis.

Treatment Strategies for EGFRm Non–Small Cell Lung Cancer With Visceral or Oligometastatic Disease

June 25th 2025

Panelists discuss how oligometastatic disease treatment requires careful definition of metastatic burden, with liver metastases potentially indicating more aggressive biology and warranting consideration of intensified frontline therapy.

Optimizing Treatment in EGFRm NSCLC With CNS Metastases: Multidisciplinary Management and Monitoring Strategies

June 25th 2025

Panelists discuss how CNS metastases in EGFR-mutated NSCLC require multidisciplinary management with close radiation oncology collaboration, frequent monitoring, and preference for FLAURA2 regimen due to superior intracranial efficacy data.

MARIPOSA in First-Line EGFRm Non–Small Cell Lung Cancer: Patient Selection and Emerging Survival Data

June 18th 2025

Panelists discuss how the MARIPOSA regimen (amivantamab plus lazertinib) shows promising overall survival benefits in first-line treatment, though with increased toxicity concerns including rash, edema, and VTE risk requiring careful patient selection.

FLAURA2 in the Frontline Management of EGFRm NSCLC: Key Considerations for Patient Selection

June 18th 2025

Panelists discuss how FLAURA2 regimen (osimertinib plus chemotherapy) is being incorporated into frontline EGFR-mutated NSCLC treatment, with considerations for escalating to combination therapy based on disease burden, CNS metastases, and patient tolerance factors.

Dr Patel on ADCs in Early-Stage NSCLC

January 7th 2025

Sandip P. Patel, MD, discusses the potential role of antibody-drug conjugates in early-stage non–small cell lung cancer.

Dr Patel on the Utility of the IPS Test in Solid Tumors

December 5th 2024

Sandip P. Patel, MD, discusses the Immune Profile Score and how it may be used to inform decisions with immune checkpoint inhibitor therapy in solid tumors.

FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLC

October 3rd 2024

Drs Patel and Stiles discuss the significance of the FDA approval of perioperative durvalumab for patients with resectable non–small cell lung cancer.

Dr Patel on Areas of Advancement in the NSCLC Treatment Landscape

July 30th 2024

Sandip P. Patel, MD, discusses significant areas of advancements in the treatment paradigm for non–small cell lung cancer.

Dr Patel on the Exploration of Sacituzumab Govitecan in NSCLC

December 20th 2023

Sandip P. Patel, MD, discusses the utilization of sacituzumab govitecan in non–small cell lung cancer, highlighting trials in which the TROP2-directed antibody-drug conjugate is being evaluated in this patient population.

Ongoing Research on HER3-DXd in NSCLC

November 9th 2023

Ticiana Leal, MD, and Sandip P. Patel, MD, discuss clinical trials evaluating the use of patritumab deruxtecan in patients with non–small cell lung cancer and remaining unmet needs.

Role of HER3-DXd in Advanced NSCLC Treatment Landscape

November 2nd 2023

Clinical insights on where patritumab deruxtecan might fit in the treatment paradigm for patients with advanced non–small cell lung cancer.

NSCLC: Safety Outcomes from HERTHENA-Lung01

November 2nd 2023

Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.

Dr Patel on the Importance of Real-World Data in Lung Cancer Treatment

October 26th 2023

Sandip P. Patel, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the continued importance of replicating clinical trial approaches in the real-world setting.

x